A new once-weekly basal insulin injection demonstrated similar efficacy and safety and a lower rate of low blood sugar episodes compared with a daily basal insulin, according to a phase 2 clinical trial. The study results compared an investigational drug called basal insulin Fc (BIF) with insulin degludec, a commercially available long-lasting daily insulin, in patients with type 2 diabetes.
source https://www.sciencedaily.com/releases/2021/03/210321215440.htm
Monday, 22 March 2021
Related Posts
Mapping the cellular circuits behind spitting in C. elegansResearchers have discovered the mechanism that underlies spitting in t… Read More
Study tests microplasma against middle-ear infectionsMiddle-ear infections are a common affliction in early life, affecting… Read More
New relevant target for PARP inhibitor talazoparibResearchers report the identification of a new target for the PARP inh… Read More
Collisions of light produce matter/antimatter from pure energyScientists studying particle collisions have produced definitive evide… Read More
Study reveals characteristics of SARS-CoV-2 spike proteinA new study provides foundational information about SARS-CoV-2's spike… Read More
Gene associated with autism linked to itch response, study findsA gene associated with autism spectrum disorder (ASD) and pain hyperse… Read More
0 comments: